We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Europe Strips AstraZeneca Of Key Nexium Patent

Law360 (December 19, 2006, 12:00 AM EST) -- In a major setback for AstraZeneca PLC, the European Patent Office has rejected a key substance-of-matter patent covering the pharmaceutical company’s blockbuster heartburn drug Nexium.

The EPO said Tuesday that it revoked the patent, which was not set to expire until 2014, following an appeal from the private German generic manufacturer Ratiopharm International GmbH. The patent had guarded the heartburn and antiulcerant medication from less expensive generic versions.

The EPO considered the validity of Nexium’s patent, which covers a slightly revised form, or enantiomer, of another...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.